Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
about
Restructuring consciousness -the psychedelic state in light of integrated information theoryThe entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugsPharmacology of hallucinations: several mechanisms for one single symptom?Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical rolesMetabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonistsIdentification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral functionDifferential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in miceHead-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.Human hallucinogen research: guidelines for safetyNeuroanatomical and neurochemical substrates of timingMystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months laterThe HIV antiretroviral drug efavirenz has LSD-like propertiesThe serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogenMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens.Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophreniaNeural correlates of the psychedelic state as determined by fMRI studies with psilocybinThe behavioral pharmacology of hallucinogensActivation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortexIdentification of a serotonin/glutamate receptor complex implicated in psychosisHigh specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligandMechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortexLysergic acid diethylamide: a drug of 'use'?Legal highs: staying on top of the flood of novel psychoactive substancesPreclinical models of antipsychotic drug action.Recent advances in the neuropsychopharmacology of serotonergic hallucinogensEpigenetic Mechanisms of Serotonin Signaling.Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humansd-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.Effects of psilocybin on time perception and temporal control of behaviour in humansSelective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRIRisperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J miceAcute Biphasic Effects of AyahuascaThe Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for PsychosisPsychedelicsThe mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophreniaMolecular substrates of schizophrenia: homeostatic signaling to connectivityModern Clinical Research on LSD.Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution.Animal Models of Psychosis: Current State and Future Directions.Animal models of serotonergic psychedelics.
P2860
Q21129375-AFA5E4BD-8BE9-4D23-B499-14A9E7DD7A06Q21129387-B708981B-BEFC-46DC-BE14-8BC861BD962AQ21284720-37DC74B6-8B79-426E-974C-B339D3306F52Q22241778-9630D63A-4529-4AD2-85D7-0EA9F2E73D12Q22251267-3D6EDE95-8A40-41B8-B4FB-B2371DB9E216Q24594672-1623C907-CB82-49C5-AB2C-DC19ED91E73DQ24594834-2B5551E9-2BA2-4B27-9AB6-D289EC1AC102Q24595389-03E3E5B1-0D27-47BA-9FD6-DE6D471EE7F6Q24600704-1B8F6FDD-8BE4-41B9-987F-33652FA9E30DQ24602685-13286695-3718-4187-B1BA-83B966CC7D93Q24606321-0D49B792-3C25-4C85-AE2C-1B7BCE6CF35BQ24608183-69F9CB28-9008-4BF2-9DBB-A38B0480F1EAQ24620468-A6F30393-2D42-4C52-8915-79159C1785D5Q24620764-FC2475B3-9C20-4114-9781-3E1D72899F26Q24632803-0D867DE5-0A93-42F5-9C8E-28A0F49C637DQ24633222-116E8326-4812-4ECD-A3C6-A9BBB090B30BQ24645656-AE98DBC8-84D4-4F9B-9695-3F8F3DD973A5Q24649779-577C4E03-C873-427F-84DE-B08216E5FB34Q24655484-B4910E5B-05D3-4F5A-9336-76A738E843FFQ24657969-F4085D5B-09D5-49E1-8B49-AADC3610F5E3Q24676304-DBE982D0-1B12-46C1-9D87-0C5DF75EF8D9Q26746133-2F375B7F-25EE-4E4B-B9EE-A85028BA8283Q26799231-D8E1258C-DBC4-4B6B-BFE0-BD8288714817Q26827502-F88508E9-5E0A-437F-BC50-394D18D3D1C3Q27027381-50B83019-16AC-4119-8922-260C8B29E955Q27027985-0DAAC5B7-0171-488E-8525-5E99A028E285Q27300685-E3CF7EC1-057B-4DC1-87B5-FB20466E70EAQ28067851-7377090F-2ABA-41D2-A8F9-7E0B4FDF2348Q28241533-659685FE-8124-4EDB-AAFB-CF80B67F1B6BQ28273159-7943D74C-537D-4A97-8DF9-7759FCA59FFBQ28397643-FC905DE1-4F40-45E9-BD7D-BE280C1BCEBEQ28548629-AA77AF84-1C72-4A6D-B688-350045BEF979Q30047193-BE3BA17A-5753-4E15-B95B-2C602C27C646Q30359998-E995C104-F3BE-4DA2-930E-337EDAFB2DB6Q30371933-DF2F9A85-C75B-4A4D-9BB5-814F49CDC187Q30383611-B63A33FA-C39C-49A1-890C-BD827049CB32Q30401421-F3937866-7CFB-4FAC-8C85-306AC5B7CF2BQ30402789-224E81A9-64EA-48D2-A2A9-C0E9DFE0BEEDQ30410153-BD4798DE-70A3-406F-ACB9-EF3C1A9FC73CQ30444312-85E02CE6-4A88-48AF-A370-8E4E8B0AEDBD
P2860
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Psilocybin induces schizophren ...... a serotonin-2 agonist action.
@ast
Psilocybin induces schizophren ...... a serotonin-2 agonist action.
@en
Psilocybin induces schizophren ...... a serotonin-2 agonist action.
@nl
type
label
Psilocybin induces schizophren ...... a serotonin-2 agonist action.
@ast
Psilocybin induces schizophren ...... a serotonin-2 agonist action.
@en
Psilocybin induces schizophren ...... a serotonin-2 agonist action.
@nl
prefLabel
Psilocybin induces schizophren ...... a serotonin-2 agonist action.
@ast
Psilocybin induces schizophren ...... a serotonin-2 agonist action.
@en
Psilocybin induces schizophren ...... a serotonin-2 agonist action.
@nl
P2093
P921
P1433
P1476
Psilocybin induces schizophren ...... a serotonin-2 agonist action.
@en
P2093
F X Vollenweider
M F Vollenweider-Scherpenhuyzen
P304
P356
10.1097/00001756-199812010-00024
P577
1998-12-01T00:00:00Z